Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

- (currently amended) A solid pharmaceutical composition comprising a synergistic combination of glimepiride and metformin <u>hydrochloride</u> or a pharmaceutically acceptable salt thereof, wherein the weight ratio of glimepiride and metformin or a pharmaceutically acceptable salt thereof is about 1/500 to about 2/500.
- 2. (canceled)
- 3. (canceled)
- 4. (previously presented) A solid pharmaceutical composition according to claim 1, comprising 500 mg metformin hydrochloride, 1 mg glimepiride, and at least one excipient.
- 5. (canceled)
- 6. (previously presented) A solid pharmaceutical composition according to claim 1 comprising 1000 mg metformin hydrochloride, 2 mg glimepiride, and at least one excipient.
- 7. (canceled)
- 8. (currently amended) A method of controlling blood glucose levels in a patient with type 2 diabetes, comprising administering to said patient a synergistic combination of glimepiride and metformin <u>hydrochloride</u> or a

pharmaceutically acceptable salt thereof, in a solid dosage form, wherein the weight ratio of glimepiride and metformin <u>hydrochloride</u> or a pharmaceutically acceptable salt thereof is about 1/500 to about 2/500.

- 9. (canceled).
- 10. (canceled)
- 11. (currently amended) A method according to claim 8 comprising administering a composition wherein glimepiride and metformin hydrochloride or a pharmaceutically acceptable salt thereof are present in amounts selected from the group consisting of (1) 1 mg glimepiride and 500 mg metformin hydrochloride; (c) and 2 mg glimepiride and 500 mg metformin hydrochloride; (c) and 2 mg glimepiride and 1000 mg metformin hydrochloride; and (d) 4 mg glimepiride and 1000 metformin hydrochloride.